Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Legend Biotech (LEGN) Operating Expenses (2019 - 2025)

Legend Biotech filings provide 7 years of Operating Expenses readings, the most recent being -$138.3 million for Q4 2025.

  • On a quarterly basis, Operating Expenses changed 0.22% to -$138.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$550.5 million, a 0.03% change, with the full-year FY2025 number at -$550.5 million, changed 0.04% from a year prior.
  • Operating Expenses hit -$138.3 million in Q4 2025 for Legend Biotech, up from -$147.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of -$79836.0 in Q1 2021 to a low of -$148.0 million in Q2 2024.
  • Median Operating Expenses over the past 5 years was -$123.8 million (2023), compared with a mean of -$107.6 million.
  • Biggest five-year swings in Operating Expenses: crashed 117898.15% in 2022 and later surged 99.87% in 2023.
  • Legend Biotech's Operating Expenses stood at -$103.6 million in 2021, then dropped by 3.66% to -$107.4 million in 2022, then surged by 99.87% to -$134390.0 in 2023, then crashed by 103032.67% to -$138.6 million in 2024, then increased by 0.22% to -$138.3 million in 2025.
  • The last three reported values for Operating Expenses were -$138.3 million (Q4 2025), -$147.9 million (Q3 2025), and -$130.9 million (Q2 2025) per Business Quant data.